EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily D Member 3-Like

Ensembl ID : ENSATEG00000002911
Gene Symbol: LOC113167986
3 Cross references
194 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSATEG00000014606
Gene Symbol: KCNQ3
1 Cross references
193 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSATEG00000012797
Gene Symbol: KCNQ5
3 Cross references
200 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2b

Ensembl ID : ENSATEG00000019922
Gene Symbol: KCNH2B
2 Cross references
186 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSATEG00000019904
Gene Symbol: PSEN1
2 Cross references
202 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSATEG00000009117
Gene Symbol: PSENEN
3 Cross references
185 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSATEG00000010053
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSATEG00000018094
Gene Symbol: LOC113157926
3 Cross references
134 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSATEG00000022772
Gene Symbol: LOC113161886
2 Cross references
145 Possible Orthologues:

Prostaglandin E Receptor 2a (Subtype Ep2)

Ensembl ID : ENSATEG00000005880
Gene Symbol: PTGER2A
3 Cross references
203 Possible Orthologues:

Prostaglandin E Receptor 2b (Subtype Ep2)

Ensembl ID : ENSATEG00000014093
Gene Symbol: PTGER2B
3 Cross references
172 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSATEG00000011448
Gene Symbol: PTGER3
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).